Related Experiment Video
Updated: May 1, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipoprotein(a) and Women's Cardiovascular Health: A Review
Erin D Michos1, Stephanie Saucier2, Roxana Mehran3
1Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Elevated lipoprotein(a) [Lp(a)] is a genetic cardiovascular disease risk factor. Understanding Lp(a) in women is crucial for managing cardiovascular risk, as levels fluctuate with hormone changes.
Area of Science:
- Cardiology
- Genetics
- Endocrinology
Background:
- Elevated lipoprotein(a) [Lp(a)] is a significant genetically determined risk factor for cardiovascular disease (CVD).
- Existing knowledge on Lp(a) levels and CVD risk specifically in women is evolving and sometimes contradictory.
- Female sex hormones critically influence lipoprotein metabolism, affecting Lp(a) levels through endogenous and exogenous estrogen exposure.
Purpose of the Study:
- To review and synthesize current knowledge on lipoprotein(a) [Lp(a)] levels and their contribution to cardiovascular disease (CVD) risk in women.
- To highlight the impact of hormonal fluctuations on Lp(a) levels throughout a woman's life.
- To emphasize the need for improved understanding and communication of Lp(a) risks among healthcare professionals for effective CVD risk management in women.
Main Methods:
- Literature review and synthesis of existing research on lipoprotein(a) [Lp(a)] and cardiovascular disease (CVD) in women.
- Analysis of the influence of female sex hormones on Lp(a) metabolism and levels.
- Discussion of current and future strategies for managing elevated Lp(a) and associated CVD risk.
Main Results:
- Lipoprotein(a) [Lp(a)] is a key genetic risk factor for cardiovascular disease (CVD).
- Lp(a) levels in women are modulated by female sex hormones, showing significant fluctuations during pregnancy and postmenopause.
- While specific Lp(a)-lowering therapies are pending, elevated Lp(a) is considered actionable for CVD risk reduction.
Conclusions:
- Healthcare professionals must be informed about the risks of elevated lipoprotein(a) [Lp(a)] in women to optimize cardiovascular disease (CVD) risk management.
- Further research into Lp(a) and women's cardiovascular health is essential for advancing CVD prevention strategies.
- Despite the absence of approved Lp(a)-lowering drugs, proactive CVD risk reduction strategies are available and necessary for women with elevated Lp(a).
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease I: Introduction

